2022 Annual Meeting | Industry Therapeutic Update from Lundbeck: Clinical and Patient Perspectives

Date Monday 04/04/22

Time 07:00 PM - 10:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives In this roundtable discussion, we will explore the burden and stigma that may be experienced by those living with a chronic condition, learn more about the efficacy and safety of VYEPTI® (eptinezumab-jjmr) and hear real patients share personal stories about living with the burden of a chronic condition and treatment with VYEPTI.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available 0.00 credit

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT	Speaker	Industry Therapeutic Update from Lundbeck: Clinical and Patient Perspectives

Faculty Disclosures
Andrew Charles, MD	Dr. Charles has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Charles has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Charles has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vectura. The institution of Dr. Charles has received research support from NIH. Dr. Charles has received publishing royalties from a publication relating to health care. Dr. Charles has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to AAN interests or activities.

��ɫ��

��ɫ��